Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female and is at least 18 years of age; scheduled to receive his or her first course of cisplatin chemotherapy at a dose of 70 mg/m2 or higher; predicted life expectancy of 3 months or greater~* Patient is post menopausal or, if premenopausal, must use double-barrier contraception~Exclusion Criteria:~* Patient has symptomatic primary or metastatic CNS malignancy~* Patient has received or will receive Radiation therapy to the abdomen or pelvis in the week prior to Treatment Day 1 though Day 6~* Patient has vomited in the 24 hours prior to treatment Day 1~* Patient has an active infection; Patient uses illicit drugs or has current evidence of alcohol abuse~* Patient is pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: study medication
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: Active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).